Appointment of Joint Broker

RNS Number : 5242A

Immupharma PLC

09 October 2009

 



FOR IMMEDIATE RELEASE

9 OCTOBER 2009

ImmuPharma PLC

("ImmuPharma")

Appointment of Joint Broker 

ImmuPharma PLC (LSE: IMM) the specialist discovery and development pharmaceutical company is pleased to announce the appointment of Noble & Company Limited ("Noble") as its joint broker with immediate effect.

Commenting on Noble's appointment, Richard Warr, Chairman of ImmuPharma said: "We are delighted to have a team as committed as Noble working with us. Over the past months they have been instrumental in attracting blue-chip funds onto ImmuPharma's share register."

- Ends -

For further information please contact: 

ImmuPharma PLC	[phone]
Dimitri Dimitriou, Chief Executive Officer  Richard Warr, Chairman
Buchanan Communications	[phone]
Lisa Baderoon
Panmure Gordon & Co                      Andrew Burnett Rakesh Sharma	[phone]
Noble & Company Limited	[phone]
James Bromhead Sam Reynolds

Notes to Editors

About ImmuPharma PLC

ImmuPharma is a drug discovery and development group with its key operations in London and subsidiaries in Mulhouse, France and Basle, Switzerland. The Company aims to develop novel drugs to treat serious medical conditions for which there is a high unmet need. It has five drugs in development to treat 1) Lupus, 2) Cancer, 3) Severe Pain, 4) Highly resistant infections like MRSA and 5) Inflammatory and Allergic disorders. 

Its lead candidate for the treatment of Lupus, LupuzorTM, a chronic, life-threatening autoimmune disease, was licensed to Cephalon, Inc in a transaction worth up to $500m in milestone payments in addition to significant royalties. $45m in cash has been received to date - $15m in Q4 2008 and $30m post year end in Q1 2009

The company also has a strong proprietary and collaborative drug development pipeline.

 

END

 

 

MSCUKAKRKURRRRA